Kyle Piskel, Chief Financial Officer at Adaptive Biotechnologies Corp.. Biography, career history and compensation sourced from SEC proxy filings.
About
Kyle Piskel has served as Adaptive Biotechnologies' Chief Financial Officer since April 2024. He joined the company in September 2015 and held roles of increasing responsibility, including Principal Accounting Officer since October 2021 and Interim Chief Financial Officer from February 2022 to June 2022. Before joining Adaptive, Mr. Piskel was an Accounting Manager at Expedia Group from October 2014 to August 2015 and worked in the Assurance services practice at Ernst & Young LLP from August 2007 to October 2014. A former certified public accountant, he holds a BA in Business Administration from Eastern Washington University and a Master of Accountancy from Gonzaga University.
Roles
Adaptive Biotechnologies Corp.
Chief Financial Officer · Current role
April 2024–present
Adaptive Biotechnologies
Chief Financial Officer
April 2024 - present
Adaptive Biotechnologies
Principal Accounting Officer
October 2021 - present
Adaptive Biotechnologies
Interim Chief Financial Officer
February 2022 - June 2022
Adaptive Biotechnologies
Roles of increasing responsibility
September 2015 - April 2024
Expedia Group
Accounting Manager
October 2014 - August 2015
Ernst & Young LLP
Assurance services practice
August 2007 - October 2014
Fixed Compensation
FY 2025
Salary
$399,950
ComponentAnnual base salary earned in FY2025
All other compensation
$4,979
Component401(k) matching contributions and related benefits
Total compensation
$3,310,729
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$203,300
Target Opportunity
—
PlanAnnual cash incentive tied to corporate and individual goals for 2025
Stock awards
Stock awards
$2,702,500
FormRSUs and performance stock units (rTSR-based), ASC 718 grant-date fair value